Dimethyl Fumarate Capsule, Delayed Release
Product Images NDC 84677-030

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dimethyl Fumarate (NDC 84677-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

84677-029-14 (Dimethyl Fumarate 120 mg REV 0626.jpg)

84677-029-14 (Dimethyl Fumarate 120 mg REV 0626.jpg)
This is a description for delayed-release capsules containing 120 mg of dimenhydrinate fumarate. The usual dosage is to take one capsule orally twice a day. It is important to keep this medication out of reach of children, store between 20°C to 25°C (68°F to 77°F), and protect the capsules from light in the original container. This medication is made in India and marketed by GSMS in Camarillo, USA.*
FDA Label Image

84677-030-60 (Dimethyl Fumarate 240mg REV 0626.jpg)

84677-030-60 (Dimethyl Fumarate 240mg REV 0626.jpg)
This is a description of Dimethyl Fumarate Delayed-Release Capsules with NDC number 84677-030-60. Each capsule contains 340 mg of fumarate, and the usual dosage is one capsule taken orally twice a day. The pharmacist should provide patient information, available at a specific website, and keep the medication out of reach of children. The capsules should be stored at 20° to 25°C and protected from light. The product is made in India by GSMS, Incorporated in Camarillo, CA.*
FDA Label Image

Figure 1: Time To 12-week Confirmed Progression Of Disability (study 1) (Dimethyl Fig1)

Figure 1: Time To 12-week Confirmed Progression Of Disability (study 1) (Dimethyl Fig1)
This is a table showing the percentage of subjects with confirmed progression of the disease (Dis) over different time points in weeks (baseline, 12, 24, 36, 48, 60, 72, and 64) for two groups: Placebo (n=408) and Dimethyl Fumarate Delayed-Release Capsules 240 mg BID (n=409).*
FDA Label Image

Dimethyl-str (Dimethyl Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.